New combo therapy aims to better control CMV in transplant patients
Disease control
Recruiting now
This study tests whether adding artesunate to standard antiviral drugs (ganciclovir or valganciclovir) can better reduce CMV virus levels in adults who have received a kidney, lung, heart, or liver transplant. About 90 participants will be randomly assigned to receive either the …
Phase: PHASE2 • Sponsor: Amivas Inc. • Aim: Disease control
Last updated May 17, 2026 12:43 UTC